RECCE PHARMACEUTICALS LTD - Announcements

Market Cap $135.6M Add to my watchlist

Healthcare

An Emerging Global Leader in the New Generation of Anti-Infective Therapies. Recce... An Emerging Global Leader in the New Generation of Anti-Infective Therapies. Recce Pharmaceuticals Ltd (ASX:RCE) is an Australian based globally-focussed, biotechnology company engaged in the development and commercialisation of a new class of synthetic anti-infectives.More

Corporate Spotlight

An Emerging Global Leader in the New Generation of Anti-Infective Therapies. Recce Pharmaceuticals Ltd (ASX:RCE) is an Australian based globally-focussed, biotechnology company engaged in the development and commercialisation of a new class of synthetic anti-infectives.
View the full Corporate Spotlight

RCE UPDATE HIGHLIGHTS KEY DEVELOPMENTS FOR UPSIDE

Announcements

Filter Results

All Price Sensitive Only

RCE	Pause in Trading	PRICE SENSITIVE	07/12/22	113.49KB	Share
RCE	Change of Director's Interest Notice - A McKeough		15/11/22	300.85KB	Share
RCE	Notification regarding unquoted securities - RCE		15/11/22	25.98KB	Share
RCE	Constitution		14/11/22	962.98KB	Share
RCE	Results of Meeting		14/11/22	248.9KB	Share
RCE	AGM Presentation		14/11/22	2.14MB	Share
RCE	Investor Presentation - Spark Plus Healthcare Day		03/11/22	2.91MB	Share
RCE	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	28/10/22	581.3KB	Share
RCE	Anti-Infective Portfolio Update and Webinar details	PRICE SENSITIVE	19/10/22	3.36MB	Share
RCE	Pause in Trading	PRICE SENSITIVE	19/10/22	115.99KB	Share
RCE	R327 COVID Study Update	PRICE SENSITIVE	18/10/22	398.4KB	Share
RCE	Pause in trading	PRICE SENSITIVE	18/10/22	115.68KB	Share
RCE	Notice of Annual General Meeting/Proxy Form		14/10/22	6.7MB	Share
RCE	Expansion and Acceleration of Clinical Programs	PRICE SENSITIVE	27/09/22	308.99KB	Share
RCE	2022 Annual General Meeting		21/09/22	227.42KB	Share
RCE	Cleansing Statement		15/09/22	193.23KB	Share
RCE	Application for quotation of securities - RCE		15/09/22	24.79KB	Share
RCE	Recce Delivers Opening R&D Address at World AMR Congress		07/09/22	4.56MB	Share
RCE	RCE Appoints Dr John Prendergast as Executive Chairman		05/09/22	235.75KB	Share
RCE	Initial Director's Interest Notice - A McKeough		01/09/22	203.01KB	Share
RCE	Recce Appoints Alistair McKeough to Board of Directors		01/09/22	234.97KB	Share
RCE	Appendix 4G		31/08/22	292.15KB	Share
RCE	Annual Report to shareholders		31/08/22	4.22MB	Share
RCE	Appendix 4E	PRICE SENSITIVE	31/08/22	244.24KB	Share
RCE	Cleansing Statement		22/08/22	201.62KB	Share
RCE	Application for quotation of securities - RCE		22/08/22	24.79KB	Share
RCE	Phase I Clinical Trial of R327 I.V. - 6000mg Complete	PRICE SENSITIVE	22/08/22	313.84KB	Share
RCE	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	01/08/22	944.67KB	Share
RCE	Corporate Presentation - Aussie Equities Day 2022	PRICE SENSITIVE	28/07/22	2.22MB	Share
RCE	Dr Philip Sutton - V.P. of Translational Sciences		11/07/22	300.48KB	Share
RCE	Phase I Positive Safety Data - 4000mg Complete	PRICE SENSITIVE	21/06/22	241.36KB	Share
RCE	Cleansing Statement		17/06/22	201.11KB	Share
RCE	Application for quotation of securities - RCE		16/06/22	24.94KB	Share
RCE	Conversion of Performance Shares		16/06/22	186KB	Share
RCE	Cleansing Statement		01/06/22	220.72KB	Share
RCE	Application for quotation of securities - RCE		01/06/22	24.8KB	Share
RCE	Phase I Clinical Trial R327 Advances to 4000mg	PRICE SENSITIVE	20/05/22	241.06KB	Share
RCE	MDC: Biotech Investors Luncheon Presentations		16/05/22	2.88MB	Share
RCE	Corporate Presentation - Biotech Investor Lunch	PRICE SENSITIVE	16/05/22	2.48MB	Share
RCE	GTG: Biotech Investors Presentation		16/05/22	2.52MB	Share
RCE	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	02/05/22	436.79KB	Share
RCE	Cleansing Statement		12/04/22	164.34KB	Share
RCE	Application for quotation of securities - RCE		12/04/22	24.79KB	Share
RCE	Phase I Clinical Trial R327 Advances to High Dose Cohort	PRICE SENSITIVE	12/04/22	408.22KB	Share
RCE	Anti-Viral Patent Granted in Hong Kong	PRICE SENSITIVE	11/04/22	225.31KB	Share
RCE	Cleansing Statement		01/04/22	162.62KB	Share
RCE	Application for quotation of securities - RCE		01/04/22	24.79KB	Share
RCE	Positive safety data from 4th Cohort -Phase I Clinical Trial	PRICE SENSITIVE	30/03/22	247.62KB	Share
RCE	$3.08m R&D Rebate Received	PRICE SENSITIVE	28/03/22	238.52KB	Share
RCE	Safety Committee Clears PhI R327 Dose Increase	PRICE SENSITIVE	07/03/22	265.52KB	Share
RCE	S&P DJI Announces March 2022 Quarterly Rebalance	PRICE SENSITIVE	04/03/22	175.5KB	Share
RCE	Appendix 4D and Interim Financial Report	PRICE SENSITIVE	28/02/22	265.76KB	Share
RCE	Positive Safety Continues in 3rd Cohort PhI Clinical Trial	PRICE SENSITIVE	21/02/22	266.79KB	Share
RCE	Cleansing Statement		11/02/22	182.42KB	Share
RCE	Notification regarding unquoted securities - RCE		11/02/22	28.94KB	Share
RCE	Application for quotation of securities - RCE		11/02/22	24.78KB	Share
RCE	Positive Safety Data from Third Cohort of PI Clinical Trial	PRICE SENSITIVE	08/02/22	247.91KB	Share
RCE	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	31/01/22	441.2KB	Share
RCE	Positive Safety Data from Second Cohort of PI Clinical Trial	PRICE SENSITIVE	18/01/22	267.69KB	Share
RCE	Positive Safety Data from Phase 1 Clinical Trial	PRICE SENSITIVE	07/01/22	316.58KB	Share
RCE	Patients to be Dosed in Ph 1 IV Clinical Trial of R327	PRICE SENSITIVE	15/12/21	246.15KB	Share
RCE	Update on Phase I/II Clinical Trial for Burn Wound Infection	PRICE SENSITIVE	07/12/21	273.37KB	Share
RCE	Results of Meeting		22/11/21	177.51KB	Share
RCE	AGM Presentation		22/11/21	2.06MB	Share
RCE	Opening R&D Address at World AMR Congress	PRICE SENSITIVE	08/11/21	6.74MB	Share
RCE	Appendix 4C and Activity Report	PRICE SENSITIVE	29/10/21	413.29KB	Share
RCE	Ethics Approval to Start Phase 1 Intravenous Clinical Trial	PRICE SENSITIVE	25/10/21	247.07KB	Share
RCE	Letter to Shareholders - Annual General Meeting		22/10/21	227.26KB	Share
RCE	Notice of General Meeting/Proxy Form		22/10/21	853.15KB	Share
RCE	Reinstatement to Official Quotation	PRICE SENSITIVE	12/10/21	85.72KB	Share
RCE	Court Orders Granted	PRICE SENSITIVE	12/10/21	404.72KB	Share
RCE	Suspension from Official Quotation	PRICE SENSITIVE	12/10/21	240.35KB	Share
RCE	Application for quotation of securities - RCE		08/10/21	24.77KB	Share
RCE	Court application and delayed cleansing notice		08/10/21	237.22KB	Share
RCE	Trading halt	PRICE SENSITIVE	08/10/21	696.71KB	Share
RCE	Pause in Trading	PRICE SENSITIVE	08/10/21	116.55KB	Share
RCE	R327 Phase I Clinical Trial Registered on ANZCTR	PRICE SENSITIVE	30/09/21	288.3KB	Share
RCE	Appendix 4G		31/08/21	269KB	Share
RCE	Annual Report to shareholders		31/08/21	5.72MB	Share
RCE	Appendix 4E	PRICE SENSITIVE	31/08/21	261.73KB	Share
RCE	Change in substantial holding		16/08/21	215.74KB	Share
RCE	Recce Receives Further Innovation Connections Grant	PRICE SENSITIVE	11/08/21	225.61KB	Share
RCE	Appendix 4C and Activity Report	PRICE SENSITIVE	30/07/21	433.45KB	Share
RCE	Corporate Presentation		27/07/21	4.64MB	Share
RCE	Anti-Viral Patent Granted in USA for RECCE Anti-Infectives	PRICE SENSITIVE	22/07/21	270.51KB	Share
RCE	Anti-Viral Patent Granted in China	PRICE SENSITIVE	20/07/21	270.49KB	Share
RCE	Outstanding Efficacy Against Flesh-Eating Bacteria	PRICE SENSITIVE	19/07/21	423.92KB	Share
RCE	Multiple Patients Dosed in Topical Phase I/II Clinical Trial	PRICE SENSITIVE	12/07/21	296.93KB	Share
RCE	Bonus Canadian R&D Rebate Received		05/07/21	267.77KB	Share
RCE	Change of Director's Interest Notices - J Graham & M Dilizia		22/06/21	436.83KB	Share
RCE	Recce Pharmaceuticals to Present at World Microbe Forum		18/06/21	307.62KB	Share
RCE	Recce to Present at MST Access Investor Conference		17/06/21	4.88MB	Share
RCE	Corporate Presentation - EU Non-Deal Roadshow		07/06/21	3.94MB	Share
RCE	Recce Clinical Pipeline Update	PRICE SENSITIVE	07/06/21	291.67KB	Share
RCE	R327 Demonstrates World First Multiple Mechanisms of Action	PRICE SENSITIVE	27/05/21	1.26MB	Share
RCE	R327 to Stage 2 of SARS-CoV-2 Antiviral Screening at CSIRO	PRICE SENSITIVE	19/05/21	328.14KB	Share
RCE	Positive Data on RECCE 327 Against All Six ESKAPE Pathogens	PRICE SENSITIVE	04/05/21	883.37KB	Share
RCE	Appendix 4C and Activity Report	PRICE SENSITIVE	27/04/21	453.68KB	Share
RCE	RECCE 327 Registered for Topical Burns Study in Humans	PRICE SENSITIVE	15/04/21	296.62KB	Share
RCE	Positive Sinusitis Patient Update - Special Access Scheme	PRICE SENSITIVE	07/04/21	300.36KB	Share

RCE Pause in Trading
07/12/22	PRICE SENSITIVE	113.49KB	Share
RCE Change of Director's Interest Notice - A McKeough
15/11/22		300.85KB	Share
RCE Notification regarding unquoted securities - RCE
15/11/22		25.98KB	Share
RCE Constitution
14/11/22		962.98KB	Share
RCE Results of Meeting
14/11/22		248.9KB	Share
RCE AGM Presentation
14/11/22		2.14MB	Share
RCE Investor Presentation - Spark Plus Healthcare Day
03/11/22		2.91MB	Share
RCE Quarterly Activities/Appendix 4C Cash Flow Report
28/10/22	PRICE SENSITIVE	581.3KB	Share
RCE Anti-Infective Portfolio Update and Webinar details
19/10/22	PRICE SENSITIVE	3.36MB	Share
RCE Pause in Trading
19/10/22	PRICE SENSITIVE	115.99KB	Share
RCE R327 COVID Study Update
18/10/22	PRICE SENSITIVE	398.4KB	Share
RCE Pause in trading
18/10/22	PRICE SENSITIVE	115.68KB	Share
RCE Notice of Annual General Meeting/Proxy Form
14/10/22		6.7MB	Share
RCE Expansion and Acceleration of Clinical Programs
27/09/22	PRICE SENSITIVE	308.99KB	Share
RCE 2022 Annual General Meeting
21/09/22		227.42KB	Share
RCE Cleansing Statement
15/09/22		193.23KB	Share
RCE Application for quotation of securities - RCE
15/09/22		24.79KB	Share
RCE Recce Delivers Opening R&D Address at World AMR Congress
07/09/22		4.56MB	Share
RCE RCE Appoints Dr John Prendergast as Executive Chairman
05/09/22		235.75KB	Share
RCE Initial Director's Interest Notice - A McKeough
01/09/22		203.01KB	Share
RCE Recce Appoints Alistair McKeough to Board of Directors
01/09/22		234.97KB	Share
RCE Appendix 4G
31/08/22		292.15KB	Share
RCE Annual Report to shareholders
31/08/22		4.22MB	Share
RCE Appendix 4E
31/08/22	PRICE SENSITIVE	244.24KB	Share
RCE Cleansing Statement
22/08/22		201.62KB	Share
RCE Application for quotation of securities - RCE
22/08/22		24.79KB	Share
RCE Phase I Clinical Trial of R327 I.V. - 6000mg Complete
22/08/22	PRICE SENSITIVE	313.84KB	Share
RCE Quarterly Activities/Appendix 4C Cash Flow Report
01/08/22	PRICE SENSITIVE	944.67KB	Share
RCE Corporate Presentation - Aussie Equities Day 2022
28/07/22	PRICE SENSITIVE	2.22MB	Share
RCE Dr Philip Sutton - V.P. of Translational Sciences
11/07/22		300.48KB	Share
RCE Phase I Positive Safety Data - 4000mg Complete
21/06/22	PRICE SENSITIVE	241.36KB	Share
RCE Cleansing Statement
17/06/22		201.11KB	Share
RCE Application for quotation of securities - RCE
16/06/22		24.94KB	Share
RCE Conversion of Performance Shares
16/06/22		186KB	Share
RCE Cleansing Statement
01/06/22		220.72KB	Share
RCE Application for quotation of securities - RCE
01/06/22		24.8KB	Share
RCE Phase I Clinical Trial R327 Advances to 4000mg
20/05/22	PRICE SENSITIVE	241.06KB	Share
RCE MDC: Biotech Investors Luncheon Presentations
16/05/22		2.88MB	Share
RCE Corporate Presentation - Biotech Investor Lunch
16/05/22	PRICE SENSITIVE	2.48MB	Share
RCE GTG: Biotech Investors Presentation
16/05/22		2.52MB	Share
RCE Quarterly Activities/Appendix 4C Cash Flow Report
02/05/22	PRICE SENSITIVE	436.79KB	Share
RCE Cleansing Statement
12/04/22		164.34KB	Share
RCE Application for quotation of securities - RCE
12/04/22		24.79KB	Share
RCE Phase I Clinical Trial R327 Advances to High Dose Cohort
12/04/22	PRICE SENSITIVE	408.22KB	Share
RCE Anti-Viral Patent Granted in Hong Kong
11/04/22	PRICE SENSITIVE	225.31KB	Share
RCE Cleansing Statement
01/04/22		162.62KB	Share
RCE Application for quotation of securities - RCE
01/04/22		24.79KB	Share
RCE Positive safety data from 4th Cohort -Phase I Clinical Trial
30/03/22	PRICE SENSITIVE	247.62KB	Share
RCE $3.08m R&D Rebate Received
28/03/22	PRICE SENSITIVE	238.52KB	Share
RCE Safety Committee Clears PhI R327 Dose Increase
07/03/22	PRICE SENSITIVE	265.52KB	Share
RCE S&P DJI Announces March 2022 Quarterly Rebalance
04/03/22	PRICE SENSITIVE	175.5KB	Share
RCE Appendix 4D and Interim Financial Report
28/02/22	PRICE SENSITIVE	265.76KB	Share
RCE Positive Safety Continues in 3rd Cohort PhI Clinical Trial
21/02/22	PRICE SENSITIVE	266.79KB	Share
RCE Cleansing Statement
11/02/22		182.42KB	Share
RCE Notification regarding unquoted securities - RCE
11/02/22		28.94KB	Share
RCE Application for quotation of securities - RCE
11/02/22		24.78KB	Share
RCE Positive Safety Data from Third Cohort of PI Clinical Trial
08/02/22	PRICE SENSITIVE	247.91KB	Share
RCE Quarterly Activities/Appendix 4C Cash Flow Report
31/01/22	PRICE SENSITIVE	441.2KB	Share
RCE Positive Safety Data from Second Cohort of PI Clinical Trial
18/01/22	PRICE SENSITIVE	267.69KB	Share
RCE Positive Safety Data from Phase 1 Clinical Trial
07/01/22	PRICE SENSITIVE	316.58KB	Share
RCE Patients to be Dosed in Ph 1 IV Clinical Trial of R327
15/12/21	PRICE SENSITIVE	246.15KB	Share
RCE Update on Phase I/II Clinical Trial for Burn Wound Infection
07/12/21	PRICE SENSITIVE	273.37KB	Share
RCE Results of Meeting
22/11/21		177.51KB	Share
RCE AGM Presentation
22/11/21		2.06MB	Share
RCE Opening R&D Address at World AMR Congress
08/11/21	PRICE SENSITIVE	6.74MB	Share
RCE Appendix 4C and Activity Report
29/10/21	PRICE SENSITIVE	413.29KB	Share
RCE Ethics Approval to Start Phase 1 Intravenous Clinical Trial
25/10/21	PRICE SENSITIVE	247.07KB	Share
RCE Letter to Shareholders - Annual General Meeting
22/10/21		227.26KB	Share
RCE Notice of General Meeting/Proxy Form
22/10/21		853.15KB	Share
RCE Reinstatement to Official Quotation
12/10/21	PRICE SENSITIVE	85.72KB	Share
RCE Court Orders Granted
12/10/21	PRICE SENSITIVE	404.72KB	Share
RCE Suspension from Official Quotation
12/10/21	PRICE SENSITIVE	240.35KB	Share
RCE Application for quotation of securities - RCE
08/10/21		24.77KB	Share
RCE Court application and delayed cleansing notice
08/10/21		237.22KB	Share
RCE Trading halt
08/10/21	PRICE SENSITIVE	696.71KB	Share
RCE Pause in Trading
08/10/21	PRICE SENSITIVE	116.55KB	Share
RCE R327 Phase I Clinical Trial Registered on ANZCTR
30/09/21	PRICE SENSITIVE	288.3KB	Share
RCE Appendix 4G
31/08/21		269KB	Share
RCE Annual Report to shareholders
31/08/21		5.72MB	Share
RCE Appendix 4E
31/08/21	PRICE SENSITIVE	261.73KB	Share
RCE Change in substantial holding
16/08/21		215.74KB	Share
RCE Recce Receives Further Innovation Connections Grant
11/08/21	PRICE SENSITIVE	225.61KB	Share
RCE Appendix 4C and Activity Report
30/07/21	PRICE SENSITIVE	433.45KB	Share
RCE Corporate Presentation
27/07/21		4.64MB	Share
RCE Anti-Viral Patent Granted in USA for RECCE Anti-Infectives
22/07/21	PRICE SENSITIVE	270.51KB	Share
RCE Anti-Viral Patent Granted in China
20/07/21	PRICE SENSITIVE	270.49KB	Share
RCE Outstanding Efficacy Against Flesh-Eating Bacteria
19/07/21	PRICE SENSITIVE	423.92KB	Share
RCE Multiple Patients Dosed in Topical Phase I/II Clinical Trial
12/07/21	PRICE SENSITIVE	296.93KB	Share
RCE Bonus Canadian R&D Rebate Received
05/07/21		267.77KB	Share
RCE Change of Director's Interest Notices - J Graham & M Dilizia
22/06/21		436.83KB	Share
RCE Recce Pharmaceuticals to Present at World Microbe Forum
18/06/21		307.62KB	Share
RCE Recce to Present at MST Access Investor Conference
17/06/21		4.88MB	Share
RCE Corporate Presentation - EU Non-Deal Roadshow
07/06/21		3.94MB	Share
RCE Recce Clinical Pipeline Update
07/06/21	PRICE SENSITIVE	291.67KB	Share
RCE R327 Demonstrates World First Multiple Mechanisms of Action
27/05/21	PRICE SENSITIVE	1.26MB	Share
RCE R327 to Stage 2 of SARS-CoV-2 Antiviral Screening at CSIRO
19/05/21	PRICE SENSITIVE	328.14KB	Share
RCE Positive Data on RECCE 327 Against All Six ESKAPE Pathogens
04/05/21	PRICE SENSITIVE	883.37KB	Share
RCE Appendix 4C and Activity Report
27/04/21	PRICE SENSITIVE	453.68KB	Share
RCE RECCE 327 Registered for Topical Burns Study in Humans
15/04/21	PRICE SENSITIVE	296.62KB	Share
RCE Positive Sinusitis Patient Update - Special Access Scheme
07/04/21	PRICE SENSITIVE	300.36KB	Share

REFRESH

First 2 3 4 5

(20min delay)
Last 66.5¢		Change 0.000(0.00%)		Mkt cap ! $135.6M

Open	High	Low	Value	Volume
66.5¢	66.5¢	65.0¢	$23.95K	36.19K

Buyers (Bids)

No.	Vol.	Price($)
1	16765	66.5¢

Sellers (Offers)

Price($)	Vol.	No.
67.0¢	74000	4

View Market Depth

No.	Vol.	Price($)
1	393	0.730
1	16765	0.665
1	25000	0.640
1	24674	0.635
1	12099	0.610

Price($)	Vol.	No.
0.670	59000	3
0.675	50000	1
0.680	28537	3
0.690	61200	2
0.695	52037	2

Last trade - 16.10pm 08/05/2024 (20 minute delay)


Last 66.5¢		Change 0.000 ( 0.00 %)
Open	High	Low	Volume
66.5¢	66.5¢	66.5¢	411
Last updated 15.06pm 08/05/2024 ?

RCE (ASX) Chart

RECCE PHARMACEUTICALS LTD - Announcements

Corporate Spotlight

Announcements

Buyers (Bids)

Sellers (Offers)

Top Stories